Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer

Authors

  • T. N. Leach,

    1. Department of Veterinary Clinical Sciences, Purdue University School of Veterinary Medicine, West Lafayette, IN, USA
    Search for more papers by this author
  • M. O. Childress,

    1. Department of Veterinary Clinical Sciences, Purdue University School of Veterinary Medicine, West Lafayette, IN, USA
    Search for more papers by this author
  • S. N. Greene,

    1. VCA Aurora Animal Hospital, Aurora, IL, USA
    Search for more papers by this author
  • A. S. Mohamed,

    1. Department of Comparative Pathobiology, Purdue University School of Veterinary Medicine, West Lafayette, IN, USA
    Search for more papers by this author
  • G. E. Moore,

    1. Department of Comparative Pathobiology, Purdue University School of Veterinary Medicine, West Lafayette, IN, USA
    Search for more papers by this author
  • D. R. Schrempp,

    1. Department of Veterinary Clinical Sciences, Purdue University School of Veterinary Medicine, West Lafayette, IN, USA
    Search for more papers by this author
  • S. R. Lahrman,

    1. Department of Veterinary Clinical Sciences, Purdue University School of Veterinary Medicine, West Lafayette, IN, USA
    Search for more papers by this author
  • D. W. Knapp

    Corresponding author
    1. Department of Veterinary Clinical Sciences, Purdue University School of Veterinary Medicine, West Lafayette, IN, USA
    2. Purdue University Center for Cancer Research, West Lafayette, IN, USA
      D. W. Knapp
      Department Veterinary Clinical Sciences
      Purdue University School of Veterinary Medicine
      Lynn Hall of Veterinary Medicine
      625 Harrison Street
      West Lafayette
      IN 47907-2026
      USA
      e-mail: knappd@purdue.edu
    Search for more papers by this author

D. W. Knapp
Department Veterinary Clinical Sciences
Purdue University School of Veterinary Medicine
Lynn Hall of Veterinary Medicine
625 Harrison Street
West Lafayette
IN 47907-2026
USA
e-mail: knappd@purdue.edu

Abstract

The purpose of this study was to assess the toxicoses and antitumor activity of metronomic chlorambucil at a dosage of 4 mg m−2 daily in dogs with naturally occurring cancer. Thirty-six dogs were enrolled in the study. The protocol was well tolerated with no grade 3 or 4 toxicoses noted. Complete remission was achieved, and lasted over 35 weeks in three dogs (mast cell tumour, soft tissue sarcoma and thyroid carcinoma). Partial remission was noted in 1 dog with histiocytic sarcoma (39 weeks duration) for an overall remission rate of 11% (4 of 36). Stable disease was noted in 17 dogs (47%) with various other cancers. The median progression-free interval was 61 days, and the median survival time was 153 days. Chlorambucil given in a metronomic protocol showed antitumor activity in dogs with a variety of naturally occurring cancers.

Ancillary